News | Radiation Therapy | November 22, 2016

RAD Technology Medical Systems Secures Two International Patents

Cancer Patients and Cancer Facilities Alike to Benefit From New Patented Technology 

radiotherapy

RAD Technology Medical Systems (RAD) is adding two new patents to its portfolio of modular building technologies for cancer treatment facilities.  RAD has received patent approvals for their Temporary Radiotherapy Vault (TRV) from both the Japanese Patent Office and the European Patent Office.  These new patents protect the specialized means and methods that RAD uses to construct high-energy radiation vaults. RAD was issued two similar patents by the United States Patent Office last year.

"As the demand for radiotherapy continues to grow worldwide, RAD is pleased to be able to bring their patented technology to help cancer patients in Europe and Japan," states RAD's President, John Lefkus.  "Hospitals and cancer clinics constantly need to upgrade equipment in order to take full advantage of the latest developments in cancer therapy and provide the best available form of treatment. Our TRV provides a treatment machine in a temporary facility that enables organizations to continue treating patients while modernizing their program with no interruption to patient treatments or business. The temporary facility can arrive onsite and be ready for occupancy in just weeks."

The RAD modular methodology is driven by three key values;

  • Time: The facility solutions offered by the RAD PRO can be delivered in one third the time of traditional construction methods. By using offsite construction, we are able to provide an unprecedented approach that is efficient and flexible. This impacts patient accessibility to the latest care and gives institutions a hedge over competitors looking to enter their market. RAD can install its TRV cancer facility and perform a radiation survey with its pre-commissioned linac in just 5 days.
  • Technology: The modular technology also provides significant value and flexibility. In traditional construction, the shielding solution is cast into the concrete structure or concrete blocks. RAD offers a shielding method that can be modified without the cost and disruption of expensive lead and high density block solutions. And the ultimate flexibility is moving the entire facility to another location at a fractional cost if demand or market conditions change.
  • Unique Financing: One of the most distinctive values is the financing approach RADs solutions offer. The modular system transforms the financing opportunities significantly. A recoverable asset, without destructive demolition, can be treated as equipment or tangible personal property allowing operational leases or service contracts to be structured for large institutions not seeking to deploy capital or wishing to avoid further impairment of their balance sheets with additional debt.

RAD continues to implement this "New Normal" in radiotherapy equipment upgrades on the international stage.  Cancer centers which were previously paralyzed by the lack of an interim solution will now be free to plan their advancements to the next generation of radiotherapy devices as the technology develops, rather than skipping whole generations of advancements as is now too often the case. As stated by Kenneth Wright, RAD Technology's Director of TRV Services, "The simple truth is that cancer centers should not be required to stop providing radiotherapy services to the community in order to improve services to the community."

Institutions in Europe are primarily state sponsored and while closing down for several months may not let the competition in, it deprives citizens of timely and perhaps lifesaving cancer treatment.  RAD has been successful in the United States with the TRV technology and leasing and now looks to continue that success in Japan and Europe.  

For more information: www.radtechnology.com

Related Content

Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation